Daewon Pharmaceutical Co., Ltd.

Equities

A003220

KR7003220001

Pharmaceuticals

End-of-day quote Korea S.E. 03:30:00 14/06/2024 am IST 5-day change 1st Jan Change
14,530 KRW -0.21% Intraday chart for Daewon Pharmaceutical Co., Ltd. -1.36% -7.22%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
SD Biotechnologies Co., Ltd. announced that it has received KRW 65 billion in funding from Koino Co.Ltd., Focus Asset Management Co., Ltd., Daewon Pharmaceutical Co., Ltd. CI
SD Biotechnologies Co., Ltd. announced that it expects to receive KRW 65 billion in funding from Koino Co.Ltd., Focus Asset Management Co., Ltd., Daewon Pharmaceutical Co., Ltd. CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
SD Biotechnologies Co., Ltd. announced that it expects to receive KRW 40 billion in funding from Daewon Pharmaceutical Co., Ltd. CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Tranche Update on Daewon Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 20, 2022. CI
Tranche Update on Daewon Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 20, 2022. CI
Daewon Pharmaceutical Co., Ltd.'s Equity Buyback announced on September 20, 2022, has expired with 361,402 shares, representing 1.71% for CNY 6,001.69 million. CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Daewon Pharmaceutical Co., Ltd. announces an Equity Buyback for 378,549 shares. CI
Daewon Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Daewon Pharmaceutical to Launch Osteoarthritis Drug in Russia MT
List Biotherapeutics, Inc. announced that it expects to receive KRW 21.342007114 billion in funding from Daewon Pharmaceutical Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm, and other investors CI
South Korean Pharmaceutical Firms Rush to Develop COVID-19 Oral Pills MT
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Daewon Pharmaceutical Co., Ltd. announced that it has received KRW 12 billion in funding from SUSUNG ASSET MANAGEMENT Co., Ltd., KB Securities Co., Ltd., Investment Arm CI
Daewon Pharmaceutical Co., Ltd. announced that it expects to receive KRW 12 billion in funding from SUSUNG ASSET MANAGEMENT Co., Ltd., KB Securities Co., Ltd., Investment Arm CI
Daewon Pharmaceutical Co., Ltd. agreed to acquire 83.5% stake in Keukdong H-Pharm Co., Ltd. for KRW 14.1 billion. CI
Tranche Update on Daewon Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 24, 2020. CI
Tranche Update on Daewon Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 24, 2020. CI
Chart Daewon Pharmaceutical Co., Ltd.
More charts
Daewon Pharmaceutical Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceutical products. The Company’s products include antipyretics, analgesics, anti-inflammatory drugs, respiratory drugs, gastrointestinal drugs, antimicrobial drugs, cardiovascular drugs, metabolic drugs, psychoneurotic drugs, neuromuscular drugs, endocrine drugs and others. The Company also produces multivitamins and health foods. The Company distributes its products within domestic market and overseas markets, including Vietnam, Myanmar, Southeast Asia, the Middle East and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
14,530 KRW
Average target price
21,000 KRW
Spread / Average Target
+44.53%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. A003220 Stock
  4. News Daewon Pharmaceutical Co., Ltd.
  5. Daewon Pharmaceutical to Launch Osteoarthritis Drug in Russia